Last Verified: | April/30/2020 |
First Submitted: | May/18/2020 |
Estimated Enrollment Submitted: | May/26/2020 |
First Posted: | May/28/2020 |
Last Update Submitted: | May/26/2020 |
Last Update Posted: | May/28/2020 |
Actual Study Start Date: | June/30/2020 |
Estimated Primary Completion Date: | June/29/2022 |
Estimated Study Completion Date: | December/30/2022 |
Study Type: | Observational |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Arm | Intervention/treatment |
---|---|
Adults with autosomal dominant polycystic kidney disease All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF). | Drug: Adults with autosomal dominant polycystic kidney disease Diagnostic aid/agent used to measure effective renal plasma flow (ERPF) |
Healthy Controls Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance). |
Ages Eligible for Study: | 18 Years to 18 Years |
Sexes Eligible for Study: | All |
Sampling method: | Probability Sample |
Accepts Healthy Volunteers: | Yes |
Criteria: | Inclusion Criteria: - Patients with Autosomal dominant polycystic kidney disease - Age 18-40 years - BMI >= 18.5 and <30 kg/m2 - Weight <350 lbs Exclusion Criteria: - Diabetes mellitus, based on previous diagnosis - Albuminuria (≥30mg/g) or estimated glomerular filtration rate (eGFR) <75ml/min/1.73m2 - Pregnancy or nursing - Anemia - Allergy to shellfish or iodine - Vaptan therapy (e.g. tolvaptan) - Uncontrolled hypertension (average ≥140/90 mmHg) |